AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01486641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach
Description: Anterolateral approach acording to Gammer for hip arthroplasty.
Study NCT01507467 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Accl. RT
Description: Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
Study NCT01507467 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accl. RT
Description: Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
Study NCT01507467 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accl. radiotherapy + Nimorazole
Description: Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
Study NCT03677050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone patient education application
Description: Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
Study NCT01886313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Civamide Nasal Spray
Study NCT01886313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05872490 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
Study NCT05872490 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
Study NCT02594423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine Needle Diathermy
Description: Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
Study NCT02594423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
Study NCT00864890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram HBr 40 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fed conditions
Study NCT00864890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CelexaTM 40 mg tablets, single dose
Description: B: Active comparator Subjects received Forest Labs formulated products under fed conditions
Study NCT03623594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical repair of the diastasis
Description: Repair of the diastasis with a double row plication using absorbable Quill suture
Study NCT01657474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly application of EpiFix plus standard of care
Study NCT01657474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biweekly application of EpiFix plus standard of care
Study NCT02147366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music & lifestyle changes
Description: Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
Study NCT02147366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
Study NCT02432222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Arts Training
Description: Visual arts training
Study NCT02432222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Training
Description: Music training
Study NCT00896779 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab
Description: Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months
Study NCT00152282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study NCT00152282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study NCT00152282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil/Premarin
Description: Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study NCT00152282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Premarin
Description: Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
Study NCT04366050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 MG Oral Capsule
Description: Include description or ramipril from protocol
Study NCT04366050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT01516840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 10 mg twice daily for 21 days, followed by 15 mg once daily
Study NCT01516840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15 mg twice daily for 21 days, followed by 15 mg once daily
Study NCT01516840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
Study NCT01516840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
Study NCT04429854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design.
Study NCT04429854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
Study NCT04429854 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care
Description: Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
Study NCT03840512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.
Study NCT02831192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: HLA mismatched donor mobilized prepheral stem cell infusion
Study NCT04143399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holmium laser enucleation of the prostate
Description: cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
Study NCT04143399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar resection of the prostate
Description: cystoscopic transurethral resection of the prostate using bipolar energy
Study NCT03366675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2811
Description: AZD2811 100mg/vial
Study NCT03078075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone: Vivitrol®
Description: Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
Study NCT03078075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB) Injectable
Description: Placebo: 4 intramuscular injections administered every 3 weeks
Study NCT03078075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion: Wellbutrin XL®
Description: Bupropion: 450 mg oral dose daily
Study NCT03078075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLB) Oral
Description: Placebo: once-daily oral placebo tablets
Study NCT00890149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron (4ug/kg bid),
Study NCT00890149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid
Study NCT00890149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS Plus
Description: Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
Study NCT00890149 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BASICS Plus
Description: Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
Study NCT03360097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frozen Embryo Transfer
Description: Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
Study NCT02114268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intravenous
Description: Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
Study NCT02114268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo on Day 1.
Study NCT02114268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intravenous
Description: Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
Study NCT02114268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intravenous
Description: Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
Study NCT02114268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intramuscular
Description: Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
Study NCT02114268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 Intramuscular
Description: Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
Study NCT02261779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Study NCT02261779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Study NCT00627302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-400
Description: Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
Study NCT00627302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
Study NCT02417155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyper/hypoventilation
Description: Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins.
Study NCT02417155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hyper/hypoventilation
Description: Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins.
Study NCT02417155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength ventilation
Description: This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
Study NCT02417155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength ventilation
Description: This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Eligibility and lifestyle restrictions check.
Description: Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Medical history, demographic and lifestyle factors
Description: Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Anthropometric measurements: height, weight, and body fat
Description: Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Blood pressure and heart rate
Description: Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Forearm blood flow: Visit 1 (EDNRA)
Description: Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Forearm blood flow: Visit 2 (EDNRA)
Description: Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Blood biochemistry (PNPLA3)
Description: 25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Blood EPCR function (PROCR)
Description: Blood sample taken will be analysed via ELISA and FACS.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Blood platelet coagulation and function (PROCR)
Description: Blood sample taken will be analysed using a Platelet coagulation and function assay.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Blood endothelial permeability (PROCR)
Description: Blood sample will be analysed in vitro using a permeability assay kit.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Blood leukocyte-endothelium adhesion (PROCR)
Description: Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Baseline Venepuncture (PNPLA3, Visit 1)
Description: Up to 25ml Blood will be taken.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Deuterium water - Loading dose 1 (PNPLA3, Visit 1)
Description: Loading dose of 3 g/kg body water.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Deuterium water - Loading dose 2 (PNPLA3, Visit 1)
Description: Loading dose of 3 g/kg body water.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Energy-balanced dinner (PNPLA3, Visit 1)
Description: Provided following baseline bloods and loading dose 1.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Fasting venepuncture (PNPLA3, Visit 2)
Description: Up to 25ml Blood will be taken.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Deuterium water - Maintenance dose (PNPLA3, Visit 2)
Description: every hour, maintenance dose 0.04 g/kg body water
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Consumption of high carbohydrate meal (PNPLA3, Visit 2)
Description: Provided following fasting blood sample.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Postprandial Venepuncture (PNPLA3, Visit 2)
Description: Up to 25ml Blood will be taken.
Study NCT03038750 — intervention group
Intervention type: OTHER
Intervention: Venepuncture (PROCR)
Description: Up to 50ml Blood will be taken.
Study NCT03483467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnigen
Description: For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
Study NCT03483467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Packaging
Description: For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
Study NCT02049268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine + Alcohol
Description: 14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
Study NCT02049268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nicotine + Alcohol
Description: Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
Study NCT02049268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine + Placebo Alcohol
Description: 14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
Study NCT01118416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV prevention intervention randomized control trial
Description: Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
Study NCT01118416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention randomized control trial
Description: Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
Study NCT04340557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
Study NCT02671045 — intervention group
Intervention type: GENETIC
Intervention: Genomic profile by FoundationOne
Description: Proprietary comprehensive genomic profile.
Study NCT02671045 — intervention group
Intervention type: GENETIC
Intervention: Genomic profile by other methods
Description: Genomic profiling by other testing methods.
Study NCT03980834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ParentCorps FUNdamentals
Description: is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
Study NCT03980834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ParentCorps 101 E-learning
Description: is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
Study NCT03980834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate